463 related articles for article (PubMed ID: 29719870)
21. Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria.
Gauba A; Rahman KM
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998792
[TBL] [Abstract][Full Text] [Related]
22. Identification of a Specific Biomarker of Acinetobacter baumannii Global Clone 1 by Machine Learning and PCR Related to Metabolic Fitness of ESKAPE Pathogens.
Álvarez VE; Quiroga MP; Centrón D
mSystems; 2023 Jun; 8(3):e0073422. PubMed ID: 37184409
[TBL] [Abstract][Full Text] [Related]
23. ESKAPE in China: epidemiology and characteristics of antibiotic resistance.
Luo Q; Lu P; Chen Y; Shen P; Zheng B; Ji J; Ying C; Liu Z; Xiao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2317915. PubMed ID: 38356197
[TBL] [Abstract][Full Text] [Related]
24. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
Saha U; Gondi R; Patil A; Saroj SD
Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial Resistance in
Lupo A; Haenni M; Madec JY
Microbiol Spectr; 2018 Jun; 6(3):. PubMed ID: 30101740
[TBL] [Abstract][Full Text] [Related]
26. Selection of Potential Probiotic Bacteria from Exclusively Breastfed Infant Faeces with Antagonistic Activity Against Multidrug-Resistant ESKAPE Pathogens.
Rastogi S; Mittal V; Singh A
Probiotics Antimicrob Proteins; 2021 Jun; 13(3):739-750. PubMed ID: 33190215
[TBL] [Abstract][Full Text] [Related]
27. The therapeutic potential of indole hybrids, dimers, and trimers against drug-resistant ESKAPE pathogens.
Qiongxian Y; Jun D; Zhenfeng Z; Tongyou L; Zhicong T; Zhenyou T
Arch Pharm (Weinheim); 2024 Jun; ():e2400295. PubMed ID: 38924571
[TBL] [Abstract][Full Text] [Related]
28. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.
Ma YX; Wang CY; Li YY; Li J; Wan QQ; Chen JH; Tay FR; Niu LN
Adv Sci (Weinh); 2020 Jan; 7(1):1901872. PubMed ID: 31921562
[TBL] [Abstract][Full Text] [Related]
29. Fine-Tuning of Alkaline Residues on the Hydrophilic Face Provides a Non-toxic Cationic α-Helical Antimicrobial Peptide Against Antibiotic-Resistant ESKAPE Pathogens.
Luo X; Ye X; Ding L; Zhu W; Yi P; Zhao Z; Gao H; Shu Z; Li S; Sang M; Wang J; Zhong W; Chen Z
Front Microbiol; 2021; 12():684591. PubMed ID: 34335511
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib Enhances the Efficacy of Low-Dose Antibiotic Treatment against Polymicrobial Sepsis in Mice and Clinical Isolates of ESKAPE Pathogens.
Annamanedi M; Varma GYN; Anuradha K; Kalle AM
Front Microbiol; 2017; 8():805. PubMed ID: 28533769
[TBL] [Abstract][Full Text] [Related]
31. Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections.
Jiang L; Lin J; Taggart CC; Bengoechea JA; Scott CJ
J Interdiscip Nanomed; 2018 Sep; 3(3):111-121. PubMed ID: 30443410
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health.
Denissen J; Reyneke B; Waso-Reyneke M; Havenga B; Barnard T; Khan S; Khan W
Int J Hyg Environ Health; 2022 Jul; 244():114006. PubMed ID: 35841823
[TBL] [Abstract][Full Text] [Related]
33. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
[TBL] [Abstract][Full Text] [Related]
34. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
Behroozian S; Svensson SL; Davies J
mBio; 2016 Jan; 7(1):e01842-15. PubMed ID: 26814180
[TBL] [Abstract][Full Text] [Related]
35. Bacteremia due to ESKAPE pathogens: An emerging problem in cancer patients.
El-Mahallawy HA; Hassan SS; El-Wakil M; Moneer MM
J Egypt Natl Canc Inst; 2016 Sep; 28(3):157-62. PubMed ID: 27268592
[TBL] [Abstract][Full Text] [Related]
36. Quorum Sensing in ESKAPE Bugs: A Target for Combating Antimicrobial Resistance and Bacterial Virulence.
Santajit S; Sookrung N; Indrawattana N
Biology (Basel); 2022 Oct; 11(10):. PubMed ID: 36290370
[TBL] [Abstract][Full Text] [Related]
37. Antibiotic resistance trends of ESKAPE pathogens in Kwazulu-Natal, South Africa: A five-year retrospective analysis.
Ramsamy Y; Essack SY; Sartorius B; Patel M; Mlisana KP
Afr J Lab Med; 2018; 7(2):887. PubMed ID: 30568908
[TBL] [Abstract][Full Text] [Related]
38. Antarctic Marine Bacteria as a Source of Anti-Biofilm Molecules to Combat ESKAPE Pathogens.
Artini M; Papa R; Vrenna G; Trecca M; Paris I; D'Angelo C; Tutino ML; Parrilli E; Selan L
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887257
[TBL] [Abstract][Full Text] [Related]
39. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
Tiwari V; Meena K; Tiwari M
Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Efflux Pump Inhibitors as Biofilm Disruptors and Resistance Breakers in Gram-Negative (ESKAPEE) Bacteria.
Reza A; Sutton JM; Rahman KM
Antibiotics (Basel); 2019 Nov; 8(4):. PubMed ID: 31752382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
